PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

Breast Cancer Female Clinical Trial

— POETIC-A  

Official title:

PreOperative Endocrine Therapy for Individualised Care With Abemaciclib

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04584853
• Other study ID #: ICRCTSU/2019/10068
• Status: Recruiting
• Phase: Phase 3
• Start date: December 23, 2020
• Est. completion date: March 31, 2032

Study information

• Verified date: January 2024
• Source: Institute of Cancer Research, United Kingdom
• Contact: Doris Lanz
• Phone: +44(0)2034376858
• Email: poetic-a-icrctsu[@]icr.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

POETIC-A is a phase 3 trial which targets post-menopausal primary breast cancer patients with a high 5-year risk of relapse as determined by a high Ki67 after 2 weeks aromatase inhibitor therapy pre-surgery. Eligible patients will be randomised to standard adjuvant endocrine therapy alone or standard adjuvant endocrine therapy with a CDK4/6 inhibitor called abemaciclib.

Description:

In women with hormone sensitive early breast cancer, taking a hormone therapy (also known as endocrine therapy) for at least five years after surgery is very effective at reducing the risk of the cancer returning. However, for some women their cancer may eventually become resistant to these drugs. POETIC-A Registration part will identify those who have a higher risk of developing resistance to standard endocrine therapy (ET). At least 8000 women diagnosed with early stage breast cancer will enter the Registration stage from 80 centres. Study doctors will use aromatase inhibitors (AIs), a type of ET, to treat the cancer for between 2 weeks and 6 months before surgery. A sample will be taken from the cancer during surgery and the study laboratory will measure a biological marker called Ki67. If the level of Ki67 does not drop after 2 weeks of AI treatment, the patient is likely to be less sensitive to endocrine therapy, and the study doctor will explore additional treatments after surgery in the POETIC-A Treatment part. Everyone who agrees to join the Treatment stage (2032 patients) will be randomly put into one of the 2 treatment groups; Group1: ET only; or Group2: ET plus a new drug called abemaciclib. The first aim of the Treatment stage is to confirm whether abemaciclib given in combination with ET is more effective than giving ET alone in preventing the cancer coming back. The study laboratory will perform a second test on the cancer sample, called an AIR-CIS test. This test aims to find out if particular groups of patients based on their tumour biology are more suitable for treatment with abemaciclib. Patients in Group 2 will receive ET plus abemaciclib for 2 years. Patients in both groups will have regular study visits during this period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2032
• Est. completion date: March 31, 2032
• Est. primary completion date: September 30, 2030
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Registration Stage Inclusion Criteria:

1. Women determined to be postmenopausal according to established local criteria.

2. Diagnosed operable invasive breast cancer with a clinical/radiological tumour size =1.0cm*

3. Grade 2 or 3 tumours

4. Preoperative full assessment completed (including bilateral breast examination and imaging with mammogram +/- ultrasound/MRI as performed locally).

5. Tumour ER positive. ER positivity is defined as >/=1% cells staining positive (or equivalent Allred Score of ER >/=3 out of 8).

6. Tumour HER2 negative or HER2 status unknown. HER2 negativity will be defined as per the 2018 ASCO/CAP updated guidelines. Patients whose HER2 status is pending/unknown at the time of registration will be allowed to register to the trial. However, please note that only patients who are confirmed to be HER2 negative will be eligible to join the randomised part.

7. Received or planned to receive 10 days to 6 months of anastrozole or letrozole prior to surgery.

8. Written informed consent to enter the registration stage of the trial and to donation of fresh tissue.

9. The patient has given written informed consent prior to any study-specific procedures and is willing and able to make herself available for the duration of the study and amenable and able to follow study schedule during treatment and follow-up and for the use of routinely collected electronic health and related records.

Registration Stage Exclusion Criteria:

1. Men and pre/perimenopausal women.

2. Intended or actual use of HRT or any other oestrogen-containing medication (including vaginal oestrogens) within 4 weeks prior to planned surgery). Note: patient with a Mirena coil in situ at the time of registration are not excluded.

3. Patients who commenced pre-surgical AI therapy >6 months prior to surgery.

4. Prior endocrine therapy for breast cancer or breast cancer prevention.

5. Prior neoadjuvant chemotherapy for breast cancer.

6. Evidence of metastatic disease.

7. Locally advanced breast cancer not amenable to surgery.

8. Bilateral invasive breast cancer (excluding contralateral DCIS/LCIS).

9. Multiple unilateral tumours with different ER and/or HER2 status. Synchronous DCIS/LCIS, as well as multifocal disease with homogenous ER/HER2 status is allowed if at least one lesion is at least 1.0cm; the largest lesion should be used for sample collection and CRF completion. If ER/HER2 status of smaller foci is unknown at time of registration, patients can be registered; however, note that congruity of receptor status will need to be confirmed by the time of randomisation, unless smaller foci are <10mm and receptor status is unknown.

10. Previous invasive breast cancer except for ipsilateral DCIS or LCIS treated >5 years previously by locoregional therapy alone or contralateral DCIS/LCIS treated by locoregional therapy at any time.

11. Any invasive malignancy diagnosed within previous 5 years (other than non-melanoma skin cancer or cervical carcinoma in situ).

12. Any other medical condition likely to exclude the patient from subsequent randomisation stage. (See exclusion criteria: Eligibility for Randomisation).

Randomisation Stage Inclusion Criteria:

1. Patient previously consented and registered for screening component of POETIC-A.

2. Tumour HER2 negative. HER2 negativity will be defined as per the 2018 ASCO/CAP updated guidelines

3. Centrally confirmed Ki67 >/=8% following 2 weeks of AI.

4. Patient is expected by the time of treatment initiation to have undergone definitive surgery for the primary breast tumour with clear radial margins as judged by the multidisciplinary team, and will have completed any adjuvant chemotherapy or radiotherapy (if prescribed).

5. Surgical staging of the axilla must have been undertaken by sentinel node biopsy, axillary sampling or dissection.

6. The patient is randomised in time for treatment to start no later than three months after completion of non-endocrine therapy (defined as the final fraction of radiotherapy, Day 1 of the final cycle of chemotherapy or the date of the final surgical procedure).

7. The patient is able to swallow oral medications (excluding transient side effects from adjuvant non-endocrine treatment, if randomised before the end of this treatment).

8. The patient intends to take adjuvant endocrine therapy for at least 5 years.

9. The patient has given written informed consent prior to any study-specific procedures (for the randomised intervention part), is willing to donate tissue from diagnostic biopsy, and is willing and able to make herself available for the duration of the study and to follow study schedule during treatment and follow-up and for the use of routinely collected electronic health and related records.

Randomisation Stage Exclusion Criteria:

1. Patient has received prior CDK4/6 inhibitor.

2. Patient is planned to receive adjuvant abemaciclib as standard of care.

3. Any patient with a history of VTE (for example, DVT of the leg or arm and/or PE) will be excluded. Patients with a history of venous catheter occlusion by thrombus that did NOT surround the catheter, and the lumen could be made patent by appropriate measures (for example, saline or thrombolytic agent), are not excluded.

4. The patient has a serious/or uncontrolled pre-existing medical condition(s) that, in the judgment of the investigator, is likely to preclude study treatment (such as severe renal impairment, [for example, estimated creatinine clearance <30 mL/min], interstitial lung disease, severe dyspnoea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or pre-existing Crohn's disease or ulcerative colitis or a pre-existing chronic condition resulting in baseline Grade 2 diarrhoea).

5. The patient has a personal history of any of the following conditions: syncope of cardiovascular aetiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: patients with controlled atrial fibrillation diagnosed more than 30 days prior to randomisation are not excluded.

6. The patient has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomisation, or is currently enrolled in any other type of medical research (for example: medical device) judged by the Chief Investigator not to be scientifically or medically compatible with this study.

7. The patient has any known active systemic bacterial infections (that would be expected to require IV antibiotics at time of initiating study treatment), systemic fungal infection or detectable viral infection (such as known HIV positivity or with known active hepatitis B or C, e.g. hepatitis B surface antigen positive) which would be expected to preclude study treatment. Screening is not required for enrolment.

8. Evidence of metastatic disease or local recurrence.

9. Multiple unilateral tumours with different ER and/or HER2 status (DCIS/LCIS are permitted, and confirmation of congruent ER/HER2 status is not necessary for lesions less than 10mm).

Week 1 Day 1 Inclusion Criteria:

1. Patient must have undergone definitive surgery for the primary breast tumour with clear radial margins as judged by the multidisciplinary team.

2. Adjuvant chemotherapy, if prescribed, must have been completed prior to Week 1 Day 1, and patients must have recovered (Common Terminology Criteria for Adverse Events, version 5 [CTCAE v5] Grade =1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to Week 1 Day 1. A washout period of a minimum of 28 days from day 1 of the last cycle of treatment is required.

3. Adjuvant radiotherapy, if prescribed, must have been completed prior to Week 1 Day 1, and patients must have recovered (Grade </=1) from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and Week 1 Day 1.

4. Week 1 Day 1 is scheduled to take place no later than three months after completion of non-endocrine therapy (defined as the final fraction of radiotherapy, Day 1 of the final cycle of chemotherapy or the date of the final surgical procedure, whichever is latest).

5. The patient is able to swallow oral medications.

6. The patient has adequate organ function for all of the following criteria defined as:

ANC >/= 1.5 × 10e9/L (G-CSF cannot be administered to meet this ANC eligibility criterion); Platelets >/= 100 × 10e9/L; Haemoglobin >/= 8g/dL; Total bilirubin </= 1.5 × ULN (Patients with Gilbert's syndrome with a total bilirubin =2.0 times ULN and direct bilirubin within normal limits are permitted); ALT and AST </= 3 × ULN

Week 1 Day 1 Exclusion Criteria:

1. Patient has received any CDK4/6 inhibitor therapy since randomisation.

2. Any newly occurring or diagnosed VTE since randomisation (for example, DVT of the leg or arm and/or PE). Note: patients with a history of venous catheter occlusion by thrombus that did NOT surround the catheter, and the lumen could be made patent by appropriate measures (for example, saline or thrombolytic agent), are not excluded.

3. Any newly occurring or diagnosed medical conditions since randomisation that, in the judgment of the investigator, would preclude participation in this study (such as severe renal impairment, [for example, estimated creatinine clearance <30 mL/min], interstitial lung disease, severe dyspnoea at rest or requiring oxygen therapy, major surgical resection involving the stomach or small bowel, or condition resulting in baseline Grade 2 diarrhoea).

4. Any newly occurring or diagnosed cardiovascular conditions since randomisation such as: syncope of cardiovascular aetiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.

5. Major surgery within 14 days prior to Week 1 Day 1.

6. The patient has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to Week 1 Day 1, or is currently enrolled in any other type of medical research (for example: medical device) judged by the Chief Investigator not to be scientifically or medically compatible with this study.

7. Any active systemic bacterial infections (requiring IV antibiotics at time of Week 1 Day 1), systemic fungal infection or detectable viral infection (such as known HIV positivity or active hepatitis B or C, e.g. hepatitis B surface antigen positive). Screening is not required for initiation of treatment.

8. Evidence of metastatic disease or local recurrence

Related Conditions & MeSH terms

• Breast Cancer Female

Intervention

Drug:
• Abemaciclib
Abemaciclib used in combination with standard Endocrine Therapy for 2 years from randomisation
• Endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen)
Standard of care endocrine therapy for a minimum of 5 years from randomisation

Locations

Country	Name	City	State
United Kingdom	Aberdeen Royal Infirmary	Aberdeen
United Kingdom	Wansbeck General Hospital	Ashington
United Kingdom	Ysbyty Gwynedd	Bangor
United Kingdom	Royal United Hospital Bath	Bath
United Kingdom	Belfast City Hospital	Belfast	Northern Ireland
United Kingdom	Royal Blackburn Hospital	Blackburn
United Kingdom	Blackpool Victoria Hospital	Blackpool
United Kingdom	Pilgrim Hospital	Boston
United Kingdom	Royal Bournemouth Hospital	Bournemouth
United Kingdom	Royal Sussex County Hospital	Brighton
United Kingdom	Burnley General Hospital	Burnley
United Kingdom	Doncaster Royal Infirmary	Doncaster
United Kingdom	Dumfries and Galloway Royal Infirmary	Dumfries
United Kingdom	Ninewells Hospital	Dundee
United Kingdom	Western General Hospital	Edinburgh
United Kingdom	Royal Devon & Exeter Hospital	Exeter	Devon
United Kingdom	The Beatson West of Scotland Cancer Centre	Glasgow
United Kingdom	Royal Surrey County Hospital	Guildford	Surrey
United Kingdom	Calderdale Royal Hospital	Halifax
United Kingdom	Harrogate District Hospital	Harrogate
United Kingdom	Huddersfield Royal Infirmary	Huddersfield
United Kingdom	Ipswich Hospital	Ipswich
United Kingdom	Kettering General Hospital	Kettering
United Kingdom	Queen Elizabeth Hospital	King's Lynn	England
United Kingdom	Kingston Hospital	Kingston Upon Thames
United Kingdom	University Hospitals of Morecambe Bay	Lancaster
United Kingdom	Forth Valley Royal Hospital	Larbert	Scotland
United Kingdom	St James's University Hospital	Leeds
United Kingdom	Lincoln County Hospital	Lincoln
United Kingdom	St John's Hospital	Livingston
United Kingdom	Barnet and Chase Farm Hospitals	London
United Kingdom	Charing Cross Hospital	London
United Kingdom	Royal Free Hospital	London
United Kingdom	Royal Marsden NHS Foundation Trust	London
United Kingdom	St George's Hospital	London
United Kingdom	University College London	London
United Kingdom	North Manchester General Hospital	Manchester
United Kingdom	The Christie Hospital	Manchester
United Kingdom	Wythenshawe Hospital	Manchester
United Kingdom	Borders General Hospital	Melrose
United Kingdom	Milton Keynes University Hospital	Milton Keynes
United Kingdom	North Tyneside General Hospital	North Shields
United Kingdom	Northampton General Hospital	Northampton	Northants
United Kingdom	University Hospital Llandough	Penarth
United Kingdom	Poole General Hospital	Poole
United Kingdom	Royal Berkshire Hospital	Reading
United Kingdom	East Surrey Hospital	Redhill
United Kingdom	Glan Clwyd	Rhyl
United Kingdom	Royal Shrewsbury Hospital	Shrewsbury
United Kingdom	Southampton General Hospital	Southampton
United Kingdom	University Hospitals of North Tees and Hartlepool	Stockton-on-Tees
United Kingdom	Royal Stoke University Hospital	Stoke-on-Trent
United Kingdom	Royal Marsden Hospital	Sutton
United Kingdom	Great Western Hospital	Swindon	England
United Kingdom	Musgrove Park Hospital	Taunton
United Kingdom	Royal Cornwall Hospital	Truro	Cornwall
United Kingdom	Mid Yorkshire -Pinderfields Hospital	Wakefield
United Kingdom	Warwick Hospital	Warwick
United Kingdom	Royal Albert Edward Infirmary	Wigan

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Cancer Research, United Kingdom

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to tumour (local or distant disease) recurrence	the time from randomisation to local, regional or distant tumour recurrence or death from breast cancer without prior notification of relapse. Second primary cancers and intercurrent deaths will be treated as censoring events.	from randomisation until tumour recurrence or patient death, assessed up to 5 years
Secondary	Relapse-free-survival	the time from randomisation to local, regional or distant tumour recurrence or death from any cause.	from randomisation until relapse or patient death, assessed up to 5 years
Secondary	Time to distant recurrence	the time from randomisation to distant tumour recurrence. Second primary cancers and intercurrent deaths will be treated as censoring events	from randomisation until distant recurrence or patient death, assessed up to 5 years
Secondary	Breast cancer specific survival	time from randomisation to death from breast cancer (with or without prior notification of relapse). Intercurrent deaths will be treated as censoring events.	from randomisation until patient death from breast cancer, assessed up to 5 years
Secondary	Overall survival	time from randomisation to death from any cause.	from randomisation until patient death, assessed up to 5 years
Secondary	Patient reported quality of life	measured using validated questionnaires which will be defined before the commencement of the relevant sub-study.	5 years from randomisation
Secondary	Grade 3/4 Adverse Events, SAEs and hospitalisations	assessed by NCI CTCAE v5	from treatment start up to 28 days after treatment discontinuation
Secondary	Treatment related deaths	defined as death occurring at any time point after randomisation and assessed to be possibly, probably or definitely related to the intervention	5 years from randomisation